News

The National Institutes of Health (NIH) has awarded a $2.87m grant to Ceragenix Pharmaceuticals to fund the pre clinical development of a Ceragenin based oral drug to treat

XOMA and Arana Therapeutics have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite

Chelsea Therapeutics has enrolled 118 randomised patients for Study 301, the second of two pivotal Phase III clinical trials in Chelsea’s registration program of Droxidopa for the treatment

Alnylam has reported that the European Patent Office (EPO) has issued a notification of intent to grant for a patent in the Kreutzer-Limmer III patent series (EP Application

Nuvilex has entered into a Joint Venture Agreement with Legacy Biotechnologies to develop and market all natural remedies for symptoms of broad spectrum flu viruses. Reportedly, as part

Oramed Pharmaceticals has received approval from the Institutional Review Board (IRB) to commence human clinical trials of an oral GLP-1 Analog. The approval was granted after successful pre-clinical

Evotec has entered into a research agreement with Biogen Idec. Under the research agreement, Evotec will screen a target selected by Biogen Idec with the option to add

Cempra Pharmaceuticals (Cempra) has initiated phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). Reportedly, the first of two pivotal trials

Targeted Genetics has sold certain assets, including manufacturing technologies and other adeno-associated viral (AAV) vector technology to Genzyme for $7m in cash. The company said, purchased assets consist